TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
Clinical trial NCT00254046 · COMPLETED
Trial details
- NCT number
- NCT00254046
- Sponsor
- Tibotec Pharmaceuticals, Ireland
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2005-11-01
- Primary completion
- 2007-02-01
- Enrollment
- 616
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.